stockrow
Friday 6 November 2026
Export SOLV’s income statement to Excel — free account
Solventum Corporation
SOLV Healthcare Medical Instruments & Supplies
Solventum Corporation’s revenue for fiscal 2025 (year ended December 2025) was $8.3 billion, up 0.86% from fiscal 2024.
- Revenue
- −7.01%
- EPS
- −101.0%
- Free cash flow
- +561.9%
- Total debt
- −90.1%
Quarter to September 2026, against a year earlier
91.31
4.13
+4.74%
Follow SOLV
Alert me
| Sep '26 From the 10-Q filed 5 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
99.04 | 9.39 | 7.95 | 8.87 |
+8 more quarters Free account |
P/S ratio |
1.84 | 1.60 | 1.38 | 1.66 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
85.06 | 58.70 | (60.19) | 145.22 | |
P/B ratio |
3.13 | 2.78 | 2.29 | 2.73 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
2.44 | 2.19 | 1.95 | 2.17 | |
EV/EBITDA |
7.70 | 7.05 | 6.18 | 6.76 | |
EV/Operating CF |
64.17 | 87.11 | 106.63 | 48.92 | |
EV/FCF |
0.00 | (154.29) | (79.32) | (1,805.27) | |
Quick Ratio |
0.52 | 0.50 | 0.52 | 0.66 | |
Current Ratio |
1.03 | 1.02 | 1.07 | 1.23 | |
Net Debt/EBITDA |
0.00 | 15.55 | 21.98 | 17.18 | |
Debt/Assets |
3.58% | 37.11% | 37.50% | 35.22% | |
Debt/Equity |
0.11 | 1.10 | 1.06 | 1.00 | |
Asset Turnover |
0.58 | 0.57 | 0.58 | 0.58 | |
Operating CF/Net income |
(14.75) | 2.47 | (14.54) | 1.51 | |
Capex/Depreciation |
(0.59) | (0.62) | (0.62) | (0.54) | |
Interest Coverage |
0.00 | 2.83 | 1.29 | 2.45 | |
Research and Development Expense of Revenue |
9.29% | 8.06% | 9.42% | 8.71% | |
Selling, General and Administrative Expense of Revenue |
41.71% | 41.96% | 41.21% | 37.99% | |
Intangible Assets out of Total Assets |
0.56 | 0.56 | 0.58 | 0.58 | |
Share Based Compensation of Revenue |
2.15% | 1.72% | 2.54% | 1.85% | |
Graham Net Nets |
(0.38) | (0.43) | (0.49) | (0.39) | |
Graham Number |
23.74 | 71.69 | 72.60 | 76.34 | |
Earnings Yield |
1.01% | 10.65% | 12.57% | 11.27% | |
Free Cash Flow Yield |
0.00% | (0.89%) | (1.78%) | (0.07%) | |
Revenue per Share |
11.41 | 12.79 | 11.52 | 11.48 | |
Operating CF per Share |
1.04 | 1.31 | (1.08) | 0.55 | |
Capex per Share |
(0.47) | (0.48) | (0.48) | (0.36) | |
Free Cash Flow per Share |
0.57 | 0.83 | (1.57) | 0.18 | |
Cash per Share |
2.64 | 2.33 | 3.22 | 5.04 | |
Shareholders Equity per Share |
28.13 | 27.79 | 28.52 | 29.00 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
28.13 | 27.79 | 28.52 | 29.00 | |
Free Cash Flow |
97.00 | 144.00 | (273.00) | 32.00 | |
Working Capital |
117.00 | 78.00 | 237.00 | 723.00 | |
Capital Expenditures |
(80.00) | (83.00) | (84.00) | (63.00) | |
Net Current Asset Value |
(5,668.00) | (5,702.00) | (5,545.00) | (5,386.00) | |
EV/EBIT |
9.58 | 8.77 | 7.63 | 8.28 | |
Capex to Sales |
0.04 | 0.04 | 0.04 | 0.03 | |
Price to Operating Income |
7.25 | 6.42 | 5.39 | 6.33 | |
| Other line items | |||||
Average Receivables |
1,283.50 | 1,343.50 | 1,145.50 | 1,206.50 | |
Average Payables |
738.50 | 672.00 | 651.50 | 652.50 | |
Average Inventory |
1,075.50 | 1,001.00 | 977.50 | 1,015.50 | |
Average Assets |
14,069.00 | 14,658.50 | 14,312.00 | 14,375.50 | |
Average Common Equity |
4,895.50 | 4,222.00 | 4,116.00 | 4,004.50 |
Columns are period end dates · fundamentals updated 5 Nov 2026